Cyprotex

Cyprotex

Evotec offers extensive nonclinical safety assessment services, from exploratory programs to GLP-compliant toxicology studies. Capabilities include dose range finding, regulatory repeat dose tox studies, specialized administration routes, ADME-PK, pathology, bioanalysis, and drug abuse liability studies. Additionally, Evotec excels in API and drug product development and manufacturing, including formulation screening to address challenges during drug discovery. This integration de-risks and accelerates IND-enabling programs for fast entry into FIH studies.
Cyprotex, an Evotec company, specializes in predictive toxicology and ADME-PK, offering high-quality in vitro assays and predictive in silico models. With state-of-the-art labs in Framingham, MA, and Alderley Park, UK, Cyprotex enhances human exposure prediction and clinical outcomes, supporting the de-risking of drug development.
Learn more at www.evotec.com and www.cyprotex.com.

ADME (Absorption/Distribution/Metabolism/Excretion), Bioanalytical Services, CRO—Contract Research Organization, Cardiology/Cardiotoxicology, In Vitro Metabolism, In Vitro Research/Testing, Modeling Products/Services, Neurobiology/Neurotoxicology, Preclinical Research/Testing, Safety Assessment